BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 1352750)

  • 1. Toward a chronotherapy of ovarian cancer with taxol. Part II: Test pilot study on circulating CA125.
    Halberg E; Long HJ; Cornélissen G; Blank MA; Elg S; Touitou Y; Bakken E; Delmore P; Haus E; Sackett-Lundeen L
    Chronobiologia; 1992; 19(1-2):17-42. PubMed ID: 1352750
    [No Abstract]   [Full Text] [Related]  

  • 2. Toward a chronotherapy of ovarian cancer with taxol. Part I: Basic background.
    Cornélissen G; Halberg E; Long HJ; Prem K; Bakken E; Touitou Y; Elg S; Haus E; Halberg F
    Chronobiologia; 1991; 18(4):153-66. PubMed ID: 1687729
    [No Abstract]   [Full Text] [Related]  

  • 3. Toward a chronotherapy of ovarian cancer. Part III: Salivary CA125 for chronochemotherapy by efficacy.
    Cornélissen G; Halberg F; Halberg E; Bingham C; Haus E; Bast RC; Fujii S; Long HJ; Halberg F; Tamura K
    Chronobiologia; 1992; 19(3-4):131-49. PubMed ID: 1362146
    [No Abstract]   [Full Text] [Related]  

  • 4. Power of chronobiologic pilots: a statistician's opinion.
    Berry DA
    Chronobiologia; 1993; 20(3-4):213-8. PubMed ID: 8131670
    [No Abstract]   [Full Text] [Related]  

  • 5. Chronome of urinary 6-sulfoxy-melatonin excretion, circulating CA125, cancer progression and therapeutic response.
    Cornélissen G; Berg H; Haus E; Halberg F
    In Vivo; 1995; 9(4):375-8. PubMed ID: 8555437
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Taxol and ovarian adenocarcinomas].
    Marty M; Extra JM; Culine S; Rousseau F
    Pathol Biol (Paris); 1992 Nov; 39(9):834-5. PubMed ID: 1347165
    [No Abstract]   [Full Text] [Related]  

  • 7. Marker rhythmometry with macrophage-colony stimulating factor (M-CSF).
    Elg S; Halberg E; Ramakrishnan S; Cornélissen G; Haus E; Nicolau G; Carson L; Twiggs L; Long HJ; Halberg F
    Chronobiologia; 1991; 18(4):141-52. PubMed ID: 1687728
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Salvage weekly paclitaxel in recurrent ovarian cancer.
    Abu-Rustum NR; Aghajanian C; Barakat RR; Fennelly D; Shapiro F; Spriggs D
    Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-62-S15-67. PubMed ID: 9346225
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intraperitoneal paclitaxel in the management of ovarian cancer.
    Markman M
    Semin Oncol; 1995 Oct; 22(5 Suppl 12):86-7. PubMed ID: 7481868
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mitoxantrone combined with paclitaxel as salvage therapy for platinum-refractory ovarian cancer: laboratory study and clinical pilot trial.
    Kurbacher CM; Bruckner HW; Cree IA; Kurbacher JA; Wilhelm L; Pöch G; Indefrei D; Mallmann P; Andreotti PE
    Clin Cancer Res; 1997 Sep; 3(9):1527-33. PubMed ID: 9815839
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Taxol: an important new drug in the management of epithelial ovarian cancer.
    Markman M
    Yale J Biol Med; 1991; 64(6):583-90. PubMed ID: 1687343
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Recurrent ovarian cancer with cancer peritonitis treated with weekly paclitaxel infusion--a clinicopharmacological study].
    Urabe S; Fujiwara H; Egawa M; Fujitou N; Sakashita T; Date K; Mizunoe T; Ueda K; Urabe T
    Gan To Kagaku Ryoho; 2004 Mar; 31(3):449-51. PubMed ID: 15045960
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Weekly paclitaxel infusion in patients with recurrent ovarian cancer--a pilot study].
    Kawagoe H; Kawata T; Nishio S; Shimomura T; Fujiyoshi K; Ishimatsu J; Tsunawaki A
    Gan To Kagaku Ryoho; 2003 Jan; 30(1):151-4. PubMed ID: 12557722
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antineoplastic activity of two taxol derivatives on an ovarian tumor xenografted into nude mice.
    Riondel J; Jacrot M; Nissou MF; Picot F; Bériel H; Mouriquand C; Potier P
    Anticancer Res; 1988; 8(3):387-90. PubMed ID: 2898915
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dose-escalated paclitaxel in 1-hour infusion with a fixed dose of cisplatin in previously untreated advanced ovarian cancer: a phase II trial of the Spanish Group for Ovarian Cancer.
    Cervantes A; Mendiola C; del Campo JM; Massuti B; Casado A; Escobedo A; Moyano A; Ojeda B; Poveda A; Benito D
    Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-40-S15-43. PubMed ID: 9346221
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Weekly paclitaxel in the management of ovarian cancer.
    Markman M
    Semin Oncol; 2000 Jun; 27(3 Suppl 7):37-40. PubMed ID: 10952125
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Circadian rhythms of tumor markers in breast cancer patients.
    Touitou Y; Bailleul F; Lévi F; Bogdan A; Touitou C; Metzger G; Mechkouri M
    Prog Clin Biol Res; 1990; 341A():59-66. PubMed ID: 2217278
    [No Abstract]   [Full Text] [Related]  

  • 18. [Feasibility, activity, and change in the level of blood paclitaxel concentration after weekly paclitaxel therapy for a patient with recurrent ovarian cancer].
    Ishioka S; Sagae S; Kudo R
    Gan To Kagaku Ryoho; 2001 Jul; 28(7):1017-21. PubMed ID: 11478132
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Toward salivary-urinary chronosensitivity testing: chronomes of OVX1, M-CSF and CA130.
    Xu F; Yu Y; Bast RC; Cornélissen G; Fujii S; Takagi M; O'Brien T; Halberg F
    In Vivo; 1995; 9(4):407-12. PubMed ID: 8555442
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prospective evaluations of continuous weekly paclitaxel regimen in recurrent platinum-resistant epithelial ovarian cancer.
    Le T; Hopkins L; Baines KA; Rambout L; Al Hayki M; Kee Fung MF
    Gynecol Oncol; 2006 Jul; 102(1):49-53. PubMed ID: 16375951
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.